Dyne Therapeutics, Inc. — Form 8-K Summary
Reporting date: September 29, 2026. The 8-K reports additional one-year clinical data for z-basivarsen (DYNE-101) in myotonic dystrophy type 1 (DM1), plus baseline data from the registrational expansion cohort of the Phase 1/2 ACHIEVE trial. The clinical disclosures were furnished under Items 7.01 and 8.01.
Financial position and performance
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial results. It refers investors to the company’s SEC filings for financial and cash-resource information.
Clinical data and material updates
- Data population: One-year results are from a pooled group of 25–26 ACHIEVE multiple-ascending-dose participants across three dose regimens. The group included participants originally assigned placebo, re-baselined before their first active dose. Only 8 of 26 received the registrational dose of 6.8 mg/kg every eight weeks throughout the full 12-month period; therefore, the pooled results do not represent continuous treatment at that dose.
- Myotonia: The pooled group’s mean baseline video hand-opening time (vHOT) was 8.2 seconds. At six months, vHOT decreased by 3.2 seconds from baseline (SD 3.5 seconds), compared with a 0.4-second increase in the ACHIEVE placebo group (N=14), a reported 3.6-second relative improvement.
- Function: At 12 months, the pooled group improved from baseline by 1.2 seconds on the five-times sit-to-stand (5xSTS) test and 0.3 seconds on the 10-meter walk/run (10MWR) test. The company reported divergence from the matched natural-history cohort on 10MWR; 5xSTS was not measured in that study.
- Strength: At 12 months, quantitative muscle testing total score and hand-grip score each improved by 4.8% predicted from baseline, with reported divergence from the matched natural-history cohort.
- Patient-reported outcomes: The Myotonic Dystrophy Health Index total score improved by 25.2% from baseline at 12 months, including improvement across six reported subscales. The comparison was against an unmatched END-DM1 natural-history cohort (N=410).
- Safety: Updated through April 20, 2026, the company reported a favorable safety and tolerability profile and no related serious treatment-emergent adverse events.
- Registrational cohort baseline: Among 71 ACHIEVE registrational expansion cohort participants, mean baseline vHOT was 8.3 seconds (SD 6.0 seconds); treatment assignments remained blinded.
Outlook, risks, and contingencies
- ACHIEVE registrational expansion cohort topline results are planned for the first quarter of 2027. The six-month change in vHOT is its primary endpoint; the company says results are intended to support a potential U.S. accelerated-approval application in the third quarter of 2027.
- The ongoing global Phase 3 HARMONIA trial uses change in 5xSTS at 12 months as its primary endpoint and is intended to serve as a confirmatory trial for traditional U.S. approval and support ex-U.S. marketing applications.
- These plans and clinical interpretations are forward-looking and uncertain. The filing highlights risks including trial execution and enrollment, whether early results predict later trials, regulatory interpretation and acceptance of endpoints or programs, approval-pathway availability, and whether cash resources will cover operating and capital needs. The filing does not quantify the company’s cash resources.
- The filing cautions that pooled data reflect mixed dose exposures and that some natural-history comparisons were matched while others were unmatched. Clinical findings and planned regulatory timelines are not assurances of approval or future outcomes.
Key facts for investors to verify
- Review the furnished press release and presentation (Exhibits 99.1 and 99.2) for complete data, analysis methods, and cohort details.
- Confirm the ACHIEVE topline timing, endpoint results, and the extent to which registrational-dose exposure is represented in the results.
- Track HARMONIA progress and whether regulators accept vHOT and the proposed accelerated-approval approach.
- Consult the company’s latest 10-Q and subsequent SEC filings for cash, liquidity, runway, and other financial metrics not included in this 8-K.